FOXO4-DRI Peptide Cycle: Three Doses Is Not a Cycle

Cycling assumes a compound that must be present to have an effect: hold a receptor occupied, sustain a signal, accumulate an adaptation, then withdraw and recover. Duration is the variable because exposure is the mechanism.

A senolytic inverts that. It eliminates a cell population, and once those cells are gone there is nothing left to act on until they re-accumulate, which happens over months and years rather than hours. Exposure beyond the point of clearance adds risk without adding benefit.

In the 2017 study, mice received FOXO4-DRI at 5 mg/kg on days 1, 3 and 5. Route was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. Doxorubicin, used to drive cells into senescence in that model, was given separately at 10 mg/kg in mice.

Three administrations, alternating days, then nothing. That is the entire published schedule, and it is an experimental design in mice rather than a template for a person.

Scaling it by body weight is a calculation you can perform and not a dose you can rely on. Allometric scaling estimates a starting point for formal study and requires pharmacokinetic inputs that do not exist for this peptide in humans: no measured half-life, no bioavailability, no clearance route.

Whatever an experimental design calls for, it starts from a concentration, and concentration starts from a mass this product does not reliably deliver.

Kovera Labs assayed batch 55-05260628 at 11.41 mg. MZ Biolabs assayed lot 55-01260229 at 8.30 mg. Both were labelled 10 mg, and both tested above 99% pure, because purity and quantity are separate measurements.

Use the certificate for your lot and our calculator. The dosage reference covers reconstitution and storage.

No cycle length, no stacking suggestions, no schedule for a person. Not because the information is withheld but because it does not exist to be given.

FOXO4-DRI holds no approval from the FDA, EMA or MHRA, and ClinicalTrials.gov lists no registered interventional study of it in humans. There is no established dose, no measured half-life in people, no tolerability data and no adverse-event record.

There is also a reason for caution beyond the absence of data. A 2023 study found that eliminating senescent cells could promote the development and progression of pulmonary hypertension, so the effects of senolysis are not uniformly in the direction people expect.